Matsuoka H, Toyama T, Horinouchi M, Maeda K, Suzuki M, Kubuki Y, Komura K, Ishikawa T, Uno H, Tsubouchi H
Second Dept. of Internal Medicine, Miyazaki Medical School.
Gan To Kagaku Ryoho. 1993 Aug;20(10):1387-90.
A 54-year-old woman with leucocytosis and skin lesion was hospitalized and diagnosed as chronic type adult T cell leukemia (ATL) in August 1989. Since her ATL cell count and LDH level increased after hospitalization, oral administration of etoposide was started at a dose of 100 mg/day for seven days. The oral administration of etoposide induced another chronic state of ATL. After 10 months without medication, she was readmitted because of an acute ATL crisis. After daily administration of etoposide at a dose of 50 mg/day, the white blood cell count and serum LDH level decreased to the normal range, and abnormal lymphocytes of peripheral blood disappeared. The low-dose daily administration of etoposide at a dose of 25 approximately 50 mg/day could be maintained over six months. No severe side effects except for alopecia and mild myelosuppression were noted during the treatment. Chronic daily administration of oral etoposide is one candidate for the treatment of ATL in an outpatient clinic.
一名54岁白细胞增多且有皮肤损害的女性于1989年8月住院,被诊断为慢性型成人T细胞白血病(ATL)。住院后其ATL细胞计数和乳酸脱氢酶(LDH)水平升高,遂开始口服依托泊苷,剂量为100毫克/天,共7天。口服依托泊苷诱发了ATL的另一种慢性状态。在停药10个月后,她因急性ATL危象再次入院。每日给予50毫克/天的依托泊苷后,白细胞计数和血清LDH水平降至正常范围,外周血异常淋巴细胞消失。低剂量每日给予约25至50毫克/天的依托泊苷可维持6个月以上。治疗期间除脱发和轻度骨髓抑制外未观察到严重副作用。门诊慢性每日口服依托泊苷是治疗ATL的一种选择。